{
  "id": 28142,
  "title": "MapLight CEO on what investors missed in the biotech’s schizophrenia data",
  "url": "https://urgent.news/2026/07/29/maplight-ceo-on-what-investors-missed-in-the-biotechs-schizophrenia",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-07-29T21:22:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/maplight-ceo-kroeger-schizophrenia-drug-trial-data-investors/826530/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the \"totality of data.\"",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}